When was Cellusion founded?

Cellusion was founded in 2015 and raised its 1st funding round 7 years after it was founded.

Where is Cellusion located?

Cellusion is headquartered in Minato City, Japan.

How many employees does Cellusion have?

As of Jun 30, 2026, the latest employee count at Cellusion is 5.

Is Cellusion a funded company?

Cellusion is a funded company, having raised a total of $32.2M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jan 06, 2022.

When was the latest funding round of Cellusion?

Cellusion's latest funding was a $***** Series C round on Jun 06, 2023, with participation from 10 investors. Its primary sector is Ophthalmology. Globally, the Ophthalmology sector has seen $1.35B in funding in 2026 to date.

Where does Cellusion rank among its competitors?

Cellusion ranks 30th amongst 93 active competitors, of which 39 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Trailhead Biosystems, which secured $20M in Jan, 2026.

Who are the top competitors of Cellusion?

Cellusion's top competitors include Aspen Neuroscience, Blue Rock Therapeutics and CorneaGen. Among them, Trailhead Biosystems secured the most recent funding round in January, 2026.

Cellusion - 2026 Company Profile, Team, Funding & Competitors

Cellusion is a series C company based in Minato City (Japan), founded in 2015. It operates as a Developer of iPS cell-based regenerative technology for bullous keratopathy. Cellusion has raised $32.2M in funding from investors like DBJ Capital, SMBC Venture Capital and UTEC. The company has 93 active competitors, including 39 funded and 8 that have exited. Its top competitors include companies like Aspen Neuroscience, Blue Rock Therapeutics and CorneaGen.

Company Details

Developer of iPS cell-based regenerative technology for bullous keratopathy. The regenerative material is developed using iPS cell-derived cell transplantation for corneal endothelium replacement. The iPS cells are injected into the cornea for treating bullous keratopathy.

Key Metrics

Founded Year

2015

Location

Minato City, Japan

Stage

Series C

Total Funding

$32.2M in 2 rounds

Latest Funding Round

Series C, Jun 06, 2023, $*****

Investors

DBJ Capital & 14 more

Ranked

30^th among 93 active competitors

Employee Count

5 as on Jun 30, 2026

Similar Companies

Aspen Neuroscience & 98 more

View Cellusion's full profile

Cellusion has raised a total funding of $32.2M over 2 rounds. Its first funding round was on Jan 06, 2022. Its latest funding round was a Series C round on Jun 06, 2023 for $*****. 10 investors participated in its latest round. Cellusion has 15 institutional investors.

Here is the list of recent funding rounds of Cellusion:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 06, 2023	2040488	Series C	1138991	5197503	2676390	5790472
Jan 06, 2022	8967636	Series B	8830901	2731698	DBJ Capital & 6 more	5146555

Access funding benchmarks and valuations. Sign up today!

View details of Cellusion's funding rounds and investors

Cellusion's employee count trend

Cellusion has 5 employees as of Jun 26. Here is Cellusion's employee count trend over the years:

Uncover Cellusion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellusion include Aspen Neuroscience, Blue Rock Therapeutics and CorneaGen. Here is the list of Top 10 competitors of Cellusion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Orbimed, Revelation Partners & 22 others	65/100
2nd	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
3rd	CorneaGen 2017, Seattle (United States), Series B	Developer of therapeutic devices for corneal transplant	$44M	Flying L Partners, CYwP Funds & 2 others	60/100
4th	EyeYon 2011, Ness Ziona (Israel), Series C	Developer of ophthalmic devices for the treatment of corneal edema	$36M	Rimonci, Pontifax & 10 others	60/100
5th	TreeFrog Therapeutics 2018, Talence (France), Series B	Developer of stem cells and organoids using proprietary technology	$84.2M	XAnge, Leonard Green and Partners & 12 others	59/100
6th	Trailhead Biosystems 2015, Beachwood (United States), Series B	Developer of cell therapies for the treatment of multiple diseases	$97.1M	MAK Capital, BioEnterprise & 1 others	57/100
7th	Morphocell Technologies 2018, Montreal (Canada), Series A	Developer of an engineered liver for the treatment of liver diseases	$50M	CQDM, Invest Quebec & 2 others	56/100
8th	Clock.bio 2020, Cambridge (United Kingdom), Seed	Developer of treatments for age-related diseases using human pluripotent stem cells	$9.93M	LocalGlobe, Skyworthdigital & 6 others	55/100
9th	Eyestem 2015, Bengaluru (India), Series B	Developer of cell replacement therapies to treat ophthamological conditions	$19.9M	Kotak Investment Advisors, Endiya Partners ... & 24 others	55/100
10th	Kenai Therapeutics 2022, San Diego (United States), Series A	Developer of allogeneic cell therapies for neurological diseases	$89M	The Column Group, Alaska Permanent Fund & 4 others	55/100
30th	Cellusion 2015, Minato City (Japan), Series C	Developer of iPS cell-based regenerative technology for bullous keratopathy	$32.2M	Mirai Creation Fund, SMBC Venture Capital ... & 13 others	40/100